This #InternationalWomensDay, we celebrate the contributions of women in science, medicine, and innovation—and reaffirm our commitment to fostering a workplace where everyone can thrive.? ? At Terns, we believe that diverse perspectives fuel innovation. By championing inclusivity, equality, and respect, we are building a culture where all voices are heard, valued, and empowered to make a difference.? ? To the women leading groundbreaking research, driving scientific progress, and inspiring future generations – thank you. Together, we can pave the way for a more equitable future. #IWD2025 #AccelerateAction?
Biotech CEO Sisterhood
生物技术研究
Inspiring a community of leaders to ignite change and drive biopharma impact.
关于我们
The Biotech CEO Sisterhood is a vibrant community dedicated to championing the success of women leaders in the biopharma industry. Rooted in a culture of mutual support and authenticity, the Sisterhood aims to inspire and uplift women while driving meaningful conversations and impact across the industry. As part of our commitment to nurturing the current and future generations of biotech leaders, the Sisterhood hosts summits, local events, and educational sessions. These programs encourage dialogue about the challenges facing women in biotech, share best practices, and enhance leadership effectiveness.
- 所属行业
- 生物技术研究
- 规模
- 201-500 人
- 类型
- 非营利机构
- 创立
- 2021
Biotech CEO Sisterhood员工
动态
-
??? Celebrating Women in Biotech | International Women’s Day 2025 ??? At RA Capital, we’re proud to recognize and celebrate the incredible women who drive innovation in biotech—scientists, investors, innovators, operators, and leaders who are inventing the future of healthcare. Despite groundbreaking progress, women remain underrepresented as biotech CEOs. We believe that needs to change. ?? To the brilliant women in our industry: We see you, we support you, and we champion your leadership. We encourage more women to step into executive roles, and we are committed to breaking down barriers that stand in the way. ?? To aspiring biotech CEOs: The industry needs your vision, resilience, and expertise. Let’s work together to create a more inclusive future in biotech leadership. #InternationalWomensDay #WomenInBiotech #LeadershipMatters #BreakingBarriers
-
-
#WomensHistoryMonth is a time to celebrate the contributions of women in healthcare and science — and to commit to advancing women in leadership. Because even though women have played a critical role in healthcare and science, leadership gaps persist. At Acadia Pharmaceuticals, we believe that advancing female leaders is a business and scientific imperative. I am proud to have a senior leadership team with amazing women leading key parts of our business including R&D, Legal, Regulatory, Medical and Commercial. Elizabeth H.Z. Thompson Jennifer J. Rhodes Holly Valdiviez Erika Parker Zavod Ponni Subbiah, Stephanie Kim ? We must challenge biases, invest in mentorship, and ensure women have the same opportunities to lead and innovate. This means advocating for them, not making assumptions about their choices, and encouraging both our daughters and sons to push for change. ? Read more on how we can drive progress: https://lnkd.in/egk2asHS
-
It’s time to change the story—with the facts to back it up. A recent analysis by Russell Reynolds Associates found key differences in how women CEOs are perceived and portrayed: — Their departures are 1.7x more likely to be reported than men’s. — When it comes to ambition, women leaders face a “double bind”: they are 2x as likely to be described as too ambitious and 2x as likely to be seen as lacking ambition altogether. — Women leaders are overwhelmingly described with people-oriented traits (empathetic, articulate, emotionally intelligent), while men are more often associated with task-oriented traits (strategic, decisive, results-driven). As the Biotech CEO Sisterhood, we believe strong leadership isn’t either/or and that great CEOs bring both strategic vision and emotional intelligence to the table. Let’s rewrite the narrative, reshape perceptions, and ensure that leadership is recognized for its impact and not outdated stereotypes. A stronger, more innovative biotech industry benefits from leveraging all talent. It’s time to make this the norm. #BiotechCEOSisterhood #WomenInLeadership #WomenLiftingWomen
-
Another amazing conversation in our channel on BiotechTV. Please check out this interview of Marianne D. De Backer, MSc, PhD, MBA by Grace Colón. They are both amazing leaders, who we are proud to have as part of the Biotech CEO Sisterhood
?????????????? ?????? ????????????????????:?Vir Biotechnology, Inc.'s CEO Marianne D. De Backer, MSc, PhD, MBA describes her background and leadership style, and joining Vir as it experienced a road bump, but turning it into an opportunity via a key IO deal. Interviewed by Biotech CEO Sisterhood editorial board member Grace Colón, Marianne De Backer advocates for the importance of getting experience in a diverse set of roles, she describes joining Vir at a time when it had experienced its first setbacks, and how a deal for a T-cell engager program has been transformational. Full video: https://lnkd.in/g2RkKye8 BiotechTV is brought to you by: Mispro | Breakthrough Properties | HSBC Innovation Banking | Allucent | Klein Hersh | Savills
-
What a great session last week! Such candid conversation and great advice to 40+ CEOs. Thanks Mintz for partnering with us to host this great event.
Earlier this week, Life Sciences, International Chair Cheryl Reicin and the Biotech CEO Sisterhood hosted an event titled ‘Structuring Life Sciences M&A and Licensing Transactions’. Cheryl and her sister Alise Reicin, MD of Tectonic Therapeutic, Inc., moderated an insightful panel discussion focusing on the business development and legal considerations one should take when structuring life sciences M&A, licensing transactions, and partnering with big pharma. The panelists included Tamara Darsow of Novo Nordisk, Sunil Patel of Merck, Manny Simons of Eli Lilly and Company and Akouos, and Nia Tatsis of Vertex Pharmaceuticals. Thank you to all who attended!
-
-
?????????????? ?????? ????????????????????: Serial entrepreneur Sheila Ann Mikhail on overcoming obstacles and getting the job done, including multiple major acquisitions in her own career. Interviewed by ReCode Therapeutics' CEO Shehnaaz Suliman, M.D. (MB ChB), M.B.A., M.Phil. for the Biotech CEO Sisterhood, she describes the journey of co-founding companies including AskBio, Bamboo Therapeutics, Chatham Therapeutics, and Viralgen VectorCore. Plus, advocacy for better breast cancer screening for all women after her own personal experience of finding a tumor that screening had missed. Full video: https://lnkd.in/g-mdtus5 BiotechTV is brought to you by: Mispro | Breakthrough Properties | HSBC Innovation Banking | Allucent | NYSE | Klein Hersh | Savills
-
Women in Biotech: Are We Moving Forward or Backward? Last year, I wrote about women's progress in biotech leadership, with women holding 20% of CEO roles and 34% of executive positions. Those numbers, while far from parity, were a beacon of hope. But a new BioSpace analysis tells a more troubling story: ?? Women now hold just 12% of CEO roles at U.S.-based public biotechs with a market cap over $100M. ?? Since October 2023, 9 of 102 biotech startups with early-stage funding had a woman CEO. ?? In the past three months, every biotech that launched or raised a Series A round was led by a man. What’s driving this? Annalee Armstrong reports that the industry’s shift toward “proven leadership”—prioritizing CEOs with previous exits—has reinforced existing biases. As a result, exceptional women with deep experience are being overlooked in favor of a familiar (and male) network. What’s the cost? 0 Fewer women CEOs mean fewer role models for the next generation. 0 Health issues primarily impacting women won’t get the attention they desperately need. (Hello, menopause) 0 Investors miss out on diverse leadership despite data showing gender-diverse teams outperform. 0 The myth of "meritocracy" persists, while unconscious bias shapes hiring decisions. ?? What can we do? ? Amplify women's success stories: if they aren’t visible, they won’t be seen as "proven leaders." ? Push for inclusive hiring & funding decisions: Despite the headlines, VCs, boards, and executives must ensure that leadership and teams reflect these companies' diverse populations. ? Create structural support: Mentorship, sponsorship, and active pathways to leadership open doors (and ceilings). The Biotech CEO Sisterhood and leaders like Sheila Gujrathi, MD and Julia Owens are fighting this retrenchment, ensuring that women aren't sidelined when the next wave of biotech founders emerge. Progress isn’t inevitable; it’s intentional. What steps do you think the industry should take to reverse this trend? #WomenInBiotech #Leadership #biotech #BiotechLeadership
-
As a biopharma community, we share a common goal to support efficient and effective U.S.-led biomedical innovation. As an industry,?our constructive engagement with the FDA ensures the?safety and efficacy of food and medicines for all Americans and allows innovative treatments to reach our communities first. We believe that excessive and indiscriminate cuts to FDA staffing?will risk delaying the approval of new medicines and could jeopardize the safety of our food supply. ? Please join us in supporting the call for the FDA to continue its critical work on behalf of all Americans.?Without continued investment and appropriate staffing, we risk slowing the pace of life-saving innovation, losing our competitive advantage, and putting patients who need new and better treatment options at risk. We encourage our industry leaders to demonstrate support for FDA by?signing this statement: https://lnkd.in/gDa695rB